Digital technology may be on the verge of ‘breaking out’ for schizophrenia treatment, but numerous questions will need to be ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Bristol Myers Squibb’s Cobenfy failed to outdistance a placebo in a Phase 3 test that evaluated the drug as an adjunct to antipsychotics in schizophrenia patients. Last September, the FDA ...

Galdieria extract blue, butterfly pea flower extract and calcium phosphate are three food colors from natural sources the FDA has approved for use in food.

The head of the Food and Drug Administration said Tuesday that the agency is now looking at whether it will still approve COVID-19 vaccines for next winter, citing a lack of data on booster shots ...

The US Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above.

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

Last year, the FDA greenlit similar self-collection cervical cancer screening kits for use in a medical setting, such as at a doctor’s office, an urgent care or even a mobile clinic.

The FDA has issued a warning about a popular hair loss drug sold by telehealth brands like Hims and Keeps, stressing that it has not been officially approved.

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy (xanomeline and trospium chloride) as an ...

The FDA is phasing out an animal testing requirement for monoclonal antibody therapies in favor of testing drugs on “lab-grown human ‘organoids.'" ...

Cobenfy, a key component in BMS’ plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback in schizophrenia.